Home › Funds › Vivo Capital, LLC › EPRX
Vivo Capital, LLC position in EPRX
Eupraxia Pharmaceuticals Inc · Health Care
Vivo Capital, LLC reported holding 1,350,000 shares of EPRX (Eupraxia Pharmaceuticals Inc) in its Q3 2026 13F filing — a position valued at US$12.3M, representing 1.39% of its reported portfolio and ranking #25 among its reported holdings. Vivo Capital, LLC has disclosed EPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's EPRX position evolved
Vivo Capital, LLC first disclosed a stake in EPRX in Q3 2025 at 1,350,000 shares (US$8.0M). The position peaked in Q3 2026 at 1,350,000 shares, worth US$12.3M. Across 5 filings, Vivo Capital, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,350,000 shares valued at US$12.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 1.35M | $7.96M | New |
| Q4 2025 | 1.35M | $10.19M | Hold |
| Q1 2026 | 1.35M | $9.77M | Hold |
| Q2 2026 | 1.35M | $8.92M | Hold |
| Q3 2026 | 1.35M | $12.29M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EPRX and 13F data
EPRX (Eupraxia Pharmaceuticals Inc) is a Health Care company. 70 other funds we track also report a position in EPRX — the largest reported positions include PFM Health Sciences, LP (US$8.0M), GREAT POINT PARTNERS LLC (US$7.9M), Ikarian Capital, LLC (US$5.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EPRX
- PFM Health Sciences, LP 1.21M sh · $8.00M · Q2 2026
- GREAT POINT PARTNERS LLC 1.20M sh · $7.93M · Q2 2026
- Ikarian Capital, LLC 809.74K sh · $5.35M · Q2 2026
- Redmile Group, LLC 611.40K sh · $4.04M · Q2 2026
- Seven Fleet Capital Management LP 610.78K sh · $4.04M · Q2 2026
- Aisling Capital Management LP 325.00K sh · $2.96M · Q3 2026
- Velan Capital Investment Management LP 352.00K sh · $2.33M · Q2 2026
- Ally Bridge Group (NY) LLC 252.18K sh · $1.67M · Q2 2026
- Delaney Capital Management Ltd. 112.40K sh · $1.03M · Q3 2026
- Lynx1 Capital Management LP 10.00K sh · $66.10K · Q2 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held EPRX?
Vivo Capital, LLC has disclosed EPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Vivo Capital, LLC's current position in EPRX?
As of Q3 2026, Vivo Capital, LLC holds 1.35M shares of EPRX (Eupraxia Pharmaceuticals Inc), valued at $12.29M, representing 1.39% of its reported portfolio and ranking #25.
Has Vivo Capital, LLC been buying or selling EPRX?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC held unchanged its position in EPRX. The position peaked in Q3 2026 at 1.35M shares.
Which other funds hold EPRX?
Other major institutional holders of EPRX include PFM Health Sciences, LP, GREAT POINT PARTNERS LLC, Ikarian Capital, LLC, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.